Affinity of new anticancer agent, DB-174, to membranes and HSA determined by fluorescence spectroscopy methods

• Autorzy: Kruszewski S. , Bom D. , Ziomkowska B. , Cyrankiewicz M.
• Języki publikacji: EN

Abstrakty

EN

The application of fluorescence spectroscopy methods to determining the properties of camptothecins promising anticancer agents are described in this paper. The fluorescence anisotropy measurements provide useful information about the binding of camptothecin and its analogues to cell membranes and human serum albumin (HSA) that is important for potential clinical applications of these agents, and permits the selection from many camptothecin analogues those ones exhibiting desirable biomedical properties. Binding properties of 7-trimethylsilyl-ethyl-10 hydroxy-camptothecin are the subject of this paper.

Słowa kluczowe

EN

camptothecin; fluorescence anisotropy; membranes; human serum albumin (HSA)

• Wydawca: Oficyna Wydawnicza Politechniki Wrocławskiej
• Czasopismo: Optica Applicata
• Rocznik: 2006
• Tom: Vol. 36, nr 2-3
• Strony: 199--207
• Opis fizyczny: Bibliogr. 12 poz.,

Twórcy

autor

Kruszewski S.

autor

Bom D.

autor

Ziomkowska B.

autor

Cyrankiewicz M.

• Collegium Medicum of N. Copernicus University ul. Jagiellońska 13, 85-067 Bydgoszcz Poland

Bibliografia

• [1] WALL M.E., WANI M.C., COOK C.E., PALMER K.H., MCPHAIL A.T., SIM G.A., Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata, Journal of the American Chemical Society 88(16), 1966, pp. 3888–90.
• [2] KOHN K.W., POMMIER Y., Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors, Annals of the New York Academy of Sciences 922, 2000, pp. 11–26.
• [3] LIU L.F., DESAI S.D., LI T.-K., MAO Y., SUN M., SIM S.-P., Mechanism of action of camptothecin, Annals of the New York Academy of Sciences 922, 2000, pp. 1–10.
• [4] LAKOWICZ J.R., Principles of Fluorescence Spectroscopy, Kluwer Academic/Plenum Publishers, New York 1999.
• [5] BURKE T.G., MI Z., The structural basis of camptothecin interactions with human serum albumin: impact on drug stability, Journal of Medicinal Chemistry 37(1), 1994, pp. 40–6.
• [6] MI Z., BURKE T.G., Differential interactions of camptothecin lactone and carboxylate forms with human blood components, Biochemistry 33(34), 1994, pp. 10325–36.
• [7] BURKE T.G., MISHRA A.K., WANI M.C., WALL M.E., Lipid bilayer partitioning and stability of camptothecin drugs, Biochemistry 32(20), 1993, pp. 5352–64.
• [8] BOM D., CURRAN D.P., KRUSZEWSKI S., ZIMMER S.G.,. STRODE J.T., KOHLHAGEN G., DU W., CHAVAN A.J., FRALEY K.A., BINGCANG A.L., LATUS L.J., POMMIER Y., BURKE T.G., The novel silatecan 7-tert-butyldimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity, Journal of Medicinal Chemistry 43(21), 2000, pp. 3970–80.
• [9] BOM D., CURRAN D.P., ZHANG J., ZIMMER S.G., BEVINS R., KRUSZEWSKI S., HOWE J.N., BINGCANG A., LATUS L.J., BURKE T.G., The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity, Journal of Controlled Release 74(1–3), 2001, pp. 325–33.
• [10] KRUSZEWSKI S., BURKE T.G., Camptothecins affinity to HSA and membranes determined by fluorescence anisotropy measurements, Optica Applicata 32(4), 2002, pp. 721–30.
• [11] BENCE A.K., MATTINGLY C.A., BURKE T.G., ADAMS V.R., The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells, Cancer Chemotherapy and Pharmacology 54(4), 2004, pp. 354–60.
• [12] BURKE T.G., TRITTON T.R., Structural basis of anthracycline selectivity for unilamellar phosphatidylcholine vesicles: an equilibrium binding study, Biochemistry 24(7), 1985, pp. 1768–76.